Fig. 8

SLC7A2 silencing enhances drug-resistance of NSCLC cells and drug treatment reduces SLC7A2 expression. The dynamic viability and proliferation of the indicated NSCLC cells in the presence of indicated concentrations of the drug were measured by CCK-8 assays. A–F The dynamic viability of A549-WT and A549-shRNA-SLC7A2. G–J The dynamic survival of H460-shRNA-Control and H460-shRNA-SLC7A2. K A549-WT cells were cultured into 6-cm dishes, and treated with 0.1 µM vinblastine, 3 µM 5-FU, 1 µM gemcitabine and 5 µM MTX for 15 days, respectively. The relative levels of SLC7A2 expression in the cells were measured by Western blot. L H460-WT cells were cultured into 6-cm dishes, and treated with 5 µM DDP, 3 nM PTX, 1 µM gemcitabine and 5 µM MTX for 15 days, respectively. The relative levels of SLC7A2 expression in the cells were measured by Western blot. Data are representative images or expressed as the mean ± SEM of each group of cells from three separate experiments